Abstract: The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently achieved.

Abstract: The present invention is directed to multiparticulate formulations for oral use, preferably comprising one or more therapeutically active agents. In particular, the present invention relates to fast melt formulations which are capable of masking the taste of the active agent, by virtue of one or more tastemasking measures, whilst retaining the desired drug dissolution profile and good mouthfeel. The multiparticulate formulations of the invention can be used in a multiple dose delivery device which dispenses a unit dose of the powder upon actuation, or can be packaged for dispensation in sachets or like unit dose containers.

Abstract: The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It also relates to methods for producing particles suitable for pulmonary inhalation, such as spray drying or jet milling.

Abstract: The present invention relates to enhancing the dosing efficiency of pharmaceutical dry powder formulations administered by pulmonary inhalation. In particular, the present invention relates to the provision of dry powder inhalers and dry powder compositions which reproducibly achieve a much higher delivered dose of the pharmaceutically active agent than currently achieved.